This is a summary of the European public assessment report (EPAR) for Movymia. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Movymia.
For practical information about using Movymia, patients should read the package leaflet or contact their doctor or pharmacist.
Movymia : EPAR - Summary for the public (PDF/81.2 KB)
First published: 16/03/2017
Last updated: 16/03/2017
Movymia : EPAR - Risk-management-plan summary (PDF/87.49 KB) (updated)
First published: 29/10/2020
Last updated: 03/11/2021
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
STADA Arzneimittel AG
|Date of issue of marketing authorisation valid throughout the European Union||
16/09/2021 Movymia - EMEA/H/C/004368 - R/0024
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Movymia is indicated in adults.
Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.
Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.